AP Biosciences, Inc. (TPEX: 6945)
Health Care · Biotechnology · TW
NT$133.00
-2.21% today · +24.3% 1Y
AP Biosciences, Inc. (TPEX: 6945) operates in the Biotechnology industry within the Health Care sector. The company is valued at $405.68M and employs 37 people.
Over the last twelve months the share price has gained 24.3%, trading between 86.10 and 236.00.
Tweenvest scores AP Biosciences, Inc. across four factors: quality 49/100, value 75/100. Its strongest factor is value.
6945 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $405.68M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -5.38
- Dividend yield
- —
- Beta (5Y)
- -0.45
- 52-week high
- NT$236.00
- 52-week low
- NT$86.10
- Avg volume (3M)
- —
- Shares outstanding
- 97.53M
- Employees
- 37
- Next earnings
- —
About AP Biosciences, Inc.
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
- ISIN
- TW0006945009
- Founded
- 2013
- Listed since
- Jul 14, 2023
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Myriad Genetics, Inc.NasdaqGS: MYGN | $412.25M | $4.20 | -2.55% |
| AVITA Medical, Inc.NasdaqCM: RCEL | $408.54M | $13.37 | +1.21% |
| Guangdong VTR Bio-Tech Co., Ltd.SZSE: 300381 | $406.47M | CN¥5.67 | -0.35% |
| GI Innovation, Inc.KOSDAQ: A358570 | $405.99M | ₩8,460.00 | -4.08% |
| Prelude Therapeutics IncorporatedNasdaqGS: PRLD | $400.65M | $3.74 | -3.86% |
| Laekna, Inc.SEHK: 2105 | $400.21M | HK$7.37 | -15.77% |
| Galectin Therapeutics Inc.NasdaqCM: GALT | $397.35M | $3.87 | -1.78% |
| Eikon Therapeutics, Inc.NasdaqGS: EIKN | $393.24M | $7.26 | -2.81% |
Figures last refreshed Oct 11, 2026.